deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT04075513

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)

A 12-week Randomized, Controlled Trial to Compare TOUJEO® and TRESIBA® in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus

Sponsor: Sanofi

Conditions Type 1 Diabetes Mellitus
Interventions Background therapy: Rapid acting insulin analogs Insulin degludec, 100U/ml Insulin glargine, 300 U/ml
Updated 17 times since 2019 Last updated: Oct 19, 2022 Started: Oct 9, 2019 Primary completion: Sep 16, 2021 Completion: Sep 16, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Type 1 Diabetes Mellitus, this trial is completed. The trial is conducted by Sanofi and has accumulated 17 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~May 2022 · 6 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE4

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE4

▶ Show 12 earlier versions

  1. Nov 2021 — May 2022 [monthly]

    Completed PHASE4

  2. Oct 2021 — Nov 2021 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  3. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  4. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

  5. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE4

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE4

  7. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  8. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE4

  9. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE4

  10. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE4

  11. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  12. Sep 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations